Please login to the form below

Not currently logged in
Email:
Password:

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

He's been with the firm since January, when he joined from Novartis

Gilead Sciences has promoted Dr Alessandro River from senior vice president, haematology and oncology therapeutic area head, to executive vice president, oncology therapeutics.

Dr Riva joined the biopharmaceutical group in January 2017, and his previous role saw him take responsibility in expanding Gilead’s oncology programme with the recent acquisition of Kite Pharma.

Prior to Gilead, Dr Riva served as head, global oncology development at Novartis, where he oversaw the development and worldwide regulatory approval of multiple compounds in a variety of tumour types.

John McHutchinson, executive vice president, clinical research, Gilead, said: “Alessandro’s vision and insight have helped Gilead broaden and deepen our oncology pipeline through the acquisition of Kite Pharma, and his exceptional leadership has guided the company’s broader haematology/oncology strategy.

“In his new role, I am confident that Gilead’s haematology and oncology programmes will continue to expand, as we seek to advance new therapies with the potential to transform the treatment of patients with cancer.”

20th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics